{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:16:50Z","timestamp":1773037010095,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1395,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Allergen specific nasal challenge (ASNC) is an optimal method to study the pathophysiological mechanisms sustaining the allergic inflammation and in particular the adhesion molecule system, which is involved in cellular infiltration of nasal mucosa. Topical steroids have been accepted as a highly effective anti\u2010inflammatory therapy for allergic rhinitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this double\u2010blind placebo\u2010 controlled study was the evaluation of clinical and cytological parameters, including ICAM\u20101 expression on nasal epithelial cells, after a 4\u2003week treatment with nasal fluticasone propionate (200 \u03bcg\/daily) or placebo, using the model of ASNC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty allergic rhinitics underwent nasal challenge before and after treatment. The following parameters were evaluated: (i) nasal symptoms (rhinorrhoea, itching, sneezing, obstruction), (ii) inflammatory cells (eosinophils and neutrophils), (iii) ICAM\u20101 expression on nasal epihelial cells at baseline, 30\u2003min (early phase) and 6\u2003h (late phase) after ASNC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fluticasone propionate was capable of reducing: (i) clinical symptoms during both early (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) and late phase (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.04), (ii) eosinophil (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.002) and neutrophil (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) infiltrate during late phase, and (iii) ICAM\u20101 expression on nasal epithelial cells during both early (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.01) and late phase (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present results demonstrate that fluticasone propionate exerts a significant action on early and late phase clinical events following specific nasal challenge, reducing also the cellular influx during the late phase. This event is likely due to the modulation of ICAM\u20101 expression on epithelial cells.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2222.1998.00239.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T09:31:13Z","timestamp":1047375073000},"page":"293-299","source":"Crossref","is-referenced-by-count":15,"title":["Intranasal fluticasone propionate reduces ICAM\u20101 on nasal epithelial cells both during early and late phase after allergen challenge"],"prefix":"10.1111","volume":"28","author":[{"family":"Ciprandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ricca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Fasolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Canonica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"597","article-title":"Mediator release after nasal airway challenge with allergen","volume":"128","author":"Naclerio RM","year":"1983","journal-title":"Am Rev Resp Dis"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90182-1"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.6.7524984"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00658.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1991.tb03199.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02734.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90112-F"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1398-9995.1994.tb00815.x","article-title":"The adhesion molecules of allergic inflammation: recent insights into their functional roles","volume":"49","author":"Canonica GW","journal-title":"Allergy"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(93)90198-O"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1996.tb00652.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1993.tb01103.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447020-00007"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02737.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02738.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1992.tb03103.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/32.2.6198355"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90217-P"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1994.tb02724.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb02735.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(93)90077-S"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90346-8"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01844202"},{"key":"e_1_2_5_24_2","unstructured":"PaolierF BattiforaM RiccioAMInhibition of adhesion molecules by budesonide on a human epithelial cell line.Allergy in press."}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2222.1998.00239.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2222.1998.00239.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2222.1998.00239.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2222.1998.00239.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T10:09:44Z","timestamp":1694426984000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2222.1998.00239.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1046\/j.1365-2222.1998.00239.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2222.1998.00239.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}